Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Reference47 articles.
1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry, Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment.
http://www.fda.gov/cber/gdlns/pharmacovig.htm
2005.
2. Health Canada. Adverse drug reaction reporting – 1998. Canadian Adverse Drug Reaction Newsletter 1999; 9: 5–6.
3. Lazarou J, Pomeranz BH, Corey PN . Incidence of adverse drug reactions in hospitalized patients – A meta-analysis of prospective studies. Journal of the American Medical Association (JAMA) 1998; 279: 1200–1205.
4. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277: 307–311.
5. Johnson JA, Bootman JL . Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995; 155: 1949–1956.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献